Novartis Ag (NVSEF) Non Operating Income (2009 - 2022)
Novartis Ag (NVSEF) posted Non Operating Income of $185.0 million for Q4 2017, up 1.09% sequentially from $183.0 million in Q3 2017, and down 65.29% YoY from $533.0 million in Q4 2016.
Novartis Ag (NVSEF) Non Operating Income (2009 - 2022) Analysis & Trends
Novartis Ag (NVSEF) has 4 years of Non Operating Income data on file, last reported at $185.0 million in Q4 2017.
- Quarterly Non Operating Income fell 65.29% year-over-year to $185.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $738.0 million (down 36.05% YoY) and the FY2017 annual result came in at $738.0 million, up 80.44% from the prior year.
- Non Operating Income improved to $185.0 million in Q4 2017 per NVSEF's latest filing, from $183.0 million in the prior quarter.
- The five-year high for Non Operating Income was $556.0 million in Q4 2015, with the low at $180.0 million in Q2 2017.
- Average Non Operating Income over 3 years is $272.0 million, with a median of $190.0 million recorded in 2017.
- The widest YoY moves for Non Operating Income: up 1.64% in 2017, down 65.29% in 2017.
- Novartis Ag's Non Operating Income stood at $556.0 million in 2015, then retreated by 4.14% to $533.0 million in 2016, then tumbled by 65.29% to $185.0 million in 2017.
- Business Quant data shows NVSEF's Non Operating Income at $185.0 million in Q4 2017, $183.0 million in Q3 2017, and $180.0 million in Q2 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -65.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -294.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -2.31 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Novartis Ag | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 920.00 Mn |
| Dec 31, 2017 | 9.88 Bn |
| Sep 30, 2017 | 183.00 Mn |
| Jun 30, 2017 | 180.00 Mn |
| Mar 31, 2017 | 190.00 Mn |
| Dec 31, 2016 | 533.00 Mn |
| Sep 30, 2016 | 212.00 Mn |
| Jun 30, 2016 | 183.00 Mn |
| Mar 31, 2016 | 226.00 Mn |
| Dec 31, 2015 | 556.00 Mn |
| Mar 31, 2014 | 765.00 |
| Mar 31, 2012 | 183.00 |
| Jun 30, 2011 | -524.00 |
| Mar 31, 2011 | 75.00 |
| Dec 31, 2010 | 785.00 |
| Sep 30, 2010 | 161.00 |
| Jun 30, 2010 | 2,368.00 Bn |
| Dec 31, 2009 | 3,422.00 Bn |
| Sep 30, 2009 | 2,156.00 |
| Jun 30, 2009 | 1,916.00 Bn |